Unidentified Analyst : Hi, this is Luke on for Brian. Thanks for taking the question. So I think you said 40 unique accounts for the 50 something completed forms. To your knowledge, do the accounts you’ve reached thus far still have patients to work through or do these existing accounts have forms filled for the majority of their patients? And then just one more do you note about like 40% of those completed enrollment forms were on therapy by the end of 3Q, you gave favorable €“ you gave color on favorable coverage determinations to the beginning of November, especially since you’re saying about half are getting reimbursed within a month at this point, if I’ve heard correctly, could you provide a general idea of what additional proportion beyond that 40% have moved on reimbursed therapy through early November? Thanks.
Scott Braunstein: Yes. Luke, it’s a good question, and I’m going to turn over to Steve and Christy, but you make a good point that people should really remember as we go through these numbers. We’re reporting the numbers through the end of September, which means if a patient got a new script the third week in September. They’re in that 40% number, right? So we’re incredibly excited that early days, early prescriptions, the carriers of both on the commercial side and even on the Medicaid side have made coverage determinations. And we continue to see that on a very regular basis, and quite honestly, the vast majority of scripts are not being delayed, not being denied. And so we could not be more enthusiastic from that standpoint. Christy, maybe I’ll turn over to you for any other comments and see if you want to add.
Christy Shafer: Yes, happy to. So Scott really pinpointed the fact that these prescriptions are coming in week by week. And so because we’ve already gotten to half of them adjudicating within 25 days to 30 days, we’re super proud of that. However, what you’re not seeing is those that came in late in September and even those that have come in now, I’d love to hit on about those 40 accounts that we’re seeing right now that have engaged in the process we’re seeing an equal number of unique healthcare providers that have prescribed as well. So not only do we have eight CDD centers of excellence that are across the United States, we also have a target base of about 265 accounts that we’re targeting today. What this tells us is that I think we got our targeting right early on here in the launch days.
And with this representation, I think that that breadth of interest not only from accounts, but physicians as well, really dictates success. I think we’ve yet to see a physician that says, I don’t have any more patients because we have an incident of about one in 40,000. We’ll continue to see patients that not only age in to two and above for our indication, but there’s going to be new patients in the database as well as we go on for the years.
Scott Braunstein: And maybe I’ll just make one other comment I think that’s important. If you think about the two big buckets here, commercial payers and Medicaid, we’re clearly making tremendous progress on the commercial side and good steady progress on Medicaid. And as we’ve always guided to in this launch, we’re confident that by early 2023 and again, Medicaid has a routine and a timeline, which is pretty ingrained both from a mandatory or optional side. But by that first quarter 2023, we’ll have the vast majority of Medicaid patients with policies in place. So we are right where we want to be. I would say we’re pleasantly ahead of schedule on the reimbursement side. And again, I think what we’re really focusing on is the cadence of new patients going forward.
And as we’ve kind of made it clear on this call, we’re really happy where we are both from the diversity of those patients and they’re not really coming solely from our centers of excellence. Steve, anything we missed that you wanted to add?
